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Abstract
Late-onset Alzheimer’s disease (LOAD) is the most common form of dementia in the elderly. The National Institute of Aging-
Late Onset Alzheimer’s Disease Family Study and the National Cell Repository for Alzheimer’s Disease conducted a joint
genome-wide association study (GWAS) of multiplex LOAD families (3,839 affected and unaffected individuals from 992
families plus additional unrelated neurologically evaluated normal subjects) using the 610 IlluminaQuad panel. This cohort
represents the largest family-based GWAS of LOAD to date, with analyses limited here to the European-American subjects.
SNPs near APOE gave highly significant results (e.g., rs2075650, p=3.2610
281), but no other genome-wide significant
evidence for association was obtained in the full sample. Analyses that stratified on APOE genotypes identified SNPs on
chromosome 10p14 in CUGBP2 with genome-wide significant evidence for association within APOE e4 homozygotes (e.g.,
rs201119, p=1.5610
28). Association in this gene was replicated in an independent sample consisting of three cohorts.
There was evidence of association for recently-reported LOAD risk loci, including BIN1 (rs7561528, p=0.009 with, and
p=0.03 without, APOE adjustment) and CLU (rs11136000, p=0.023 with, and p=0.008 without, APOE adjustment), with
weaker support for CR1. However, our results provide strong evidence that association with PICALM (rs3851179, p=0.69
with, and p=0.039 without, APOE adjustment) and EXOC3L2 is affected by correlation with APOE, and thus may represent
spurious association. Our results indicate that genetic structure coupled with ascertainment bias resulting from the strong
APOE association affect genome-wide results and interpretation of some recently reported associations. We show that a
locus such as APOE, with large effects and strong association with disease, can lead to samples that require appropriate
adjustment for this locus to avoid both false positive and false negative evidence of association. We suggest that similar
adjustments may also be needed for many other large multi-site studies.
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Alzheimer’s disease (AD, MIM 104300) is by far the most
common form of dementia in the elderly. Late onset Alzheimer’s
disease (LOAD), defined by the onset of symptoms after age 60
years, has annual incidence rates increasing from 1% at 65–70
years to 6–8% at 85 years and older [1]. By age 85 years and up,
prevalence is 10–30% or more [2]. While the underlying causes of
LOAD are still unknown, there is ample evidence for genetic
factors affecting risk, including high estimated heritability of
LOAD (58–79%) [3], and evidence from both twin [4,5] and
family studies [6–9].
A small number of genes have been identified in which variation
contributes to Alzheimer’s disease risk. Multiplex early-onset
Alzheimer’s disease (EOAD) pedigrees [10–12] facilitated the
identification of mutations in three genes: the amyloid precursor
protein (APP) [13], presenilin 1 (PSEN1) [14] and presenilin 2
(PSEN2) [15]. In contrast to the success in familial EOAD, only
one gene, APOE, is an unequivocally established ‘‘susceptibility’’
gene for LOAD [16], with the e4 allele associated with increased
risk in a dose-dependent manner and the e2 allele with decreased
risk [17]. There is incomplete lifetime penetrance even in the
highest-risk APOE genotypes [18], and the fraction of genetic
variance for LOAD risk attributed to APOE is estimated as only
10–20% [19,20]. This, coupled with results of oligogenic
segregation analyses supporting the presence of at least 4–6
additional major genes [21,22], suggests that additional risk loci
remain to be discovered.
Multiple approaches have been used to identify additional loci
contributing to LOAD. Several regions have been implicated as a
result of multiple linkage-based genome scans [23–32]. With the
exception of the APOE gene region, there is only modest overlap
among the chromosomal regions identified by different analyses
[33], and it has been difficult to identify causal variants. Multiple
genome-wide association studies (GWAS) of unrelated subjects
have now also been carried out [34–44]. With the exception of
single nucleotide polymorphisms (SNPs) near APOE, all associated
SNPs in these studies have had small estimated effect sizes, with
odds ratios reported in the range of 1.1 to 1.5, and also with little
overlap among studies. Such estimated odds ratios are likely to be
highly inflated, and the true effects much smaller [45],
complicating replication and identification of causal variants.
However, among recent GWAS studies, a small number of loci
have shown some evidence for replication across samples including
clusterin (CLU), phosphatidylinositol binding clathrin assembly
protein (PICALM) and complement component (3b/4b) receptor 1
(CR1) [42–44].
The use of densely affected families with LOAD, which are
expected to carry higher frequencies of risk alleles, is an excellent
alternative method of identifying additional genes contributing to
LOAD. For example, the APOE-e4 frequency is higher in LOAD
cases with a positive family history than in sporadic LOAD cases
[46,47]. Compared to the more typical use of unrelated subjects,
often without a family history of LOAD, family-based designs may
enrich for variants with higher penetrance and consequent
increase in odds ratios, and thus increase the power for their
detection [48]. Such families can be used in both linkage and
association-based designs, with appropriate correction for inclu-
sion of related individuals [38].
Here we present results from a GWAS in multiplex LOAD
families. Unlike many other studies, unaffected relatives were also
evaluated and are included to increase the amount of genetic
information and to provide additional phenotypes that can be used
in subsequent analyses. A supplementary control group consisting
of unrelated individuals was also recruited and underwent the
same phenotypic evaluation. Thus, this cohort represents the
largest family-based GWAS of LOAD to date, allowing us to
explore issues related to stratification as well as providing a
powerful approach for detailed modeling of the effects of APOE in
the search for other novel risk loci in LOAD. The genotypic and
phenotypic data generated in this study are part of the NIA-
LOAD/NCRAD family study (http://ncrad.iu.edu) and are
available to the research community through dbGaP (http://
www.ncbi.nlm.nih.gov/gap). Biological samples from these well-
characterized individuals and families are also available through
NCRAD. Our results implicate a new region on chromosome 10p
in individuals with the APOE e4/e4 genotype, and provide support
for some of the recently implicated loci. They also suggest that
sample structure and ascertainment bias related to the strong
APOE association with AD risk are important confounders. This
affects the interpretation of some of the recently implicated loci as
well as other GWAS studies of LOAD.
Methods
Subjects and Sample
Subjects. The patient sample contained individuals from
families as well as unrelated individuals; however, all patients with
LOAD had a family history of Alzheimer’s disease. All patients
were recruited after providing informed consent and with approval
by the relevant institutional review boards, and the study was
conducted according to the principles expressed in the Declaration
of Helsinki. Regardless of the source (NIA-LOAD Family Study or
NCRAD), patients and families were required to meet the same
study criteria. In the families, probands were required to have a
diagnosis of definite or probable LOAD [49] with onset .60 years
of age and a sibling with definite, probable or possible LOAD with
a similar age at onset. A third biologically-related family member
was required, who could have been a first-, second-, or third-
degree relative of the affected sibling pairs, and who was 60 years
of age or older if unaffected, or 50 years of age if diagnosed with
LOAD or mild cognitive impairment [50]. In these families,
additional relatives over age 50 years were recruited regardless of
cognitive status. Persons deemed unaffected (controls) were
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Genetic factors are well-established to play a role in risk of
Alzheimer’s disease (AD). However, it has been difficult to
find genes that are involved in AD susceptibility, other
than a small number of genes that play a role in early-
onset, high-penetrant disease risk, and the APOE e4 allele,
which increases risk of late-onset disease. Here we use a
European-American family-based sample to examine the
role of common genetic variants on late-onset AD. We
show that variants in CUGBP2 on chromosome 10p, along
with nearby variants, are associated with AD in those
highest-risk APOE e4 homozygotes. We have replicated this
interaction in an independent sample. CUGBP2 has one
isoform that is expressed predominantly in neurons, and
identification of such a new risk locus is important because
of the severity of AD. We also provide support for recently
proposed associated variants (BIN1, CLU, and partly CR1)
and show that there are markers throughout the genome
that are correlated with APOE. This emphasizes the need to
adjust for APOE for such markers to avoid false associations
and suggests that there may be confounding for other
diseases with similar strong risk loci.
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examination to verify this clinical designation. The largest
component of the dataset consisted of 607 families (1,516
affected, 1,306 unaffected) from the NIA-LOAD Family Study
and 138 families from the National Cell Repository for Alzheimer
Disease (NCRAD; 337 affected, 166 unknown intermediate
phenotypes; see Figure S1). We also included pairs of affected
siblings whose third family member was either too young, not
sampled at the time of the investigation, or had died before an
evaluation and blood sample could be obtained. Another 471
unrelated patients from the NIA-LOAD Family Study and
NCRAD were included in order to enhance sample size and
because they had a well-documented family history of dementia,
although no other participating family members had as yet been
examined at the time of the investigation.
Unrelated controls were ascertained through three sources: the
NIA-LOAD Family Study (n=794), and NCRAD (n=144), with
the NCRAD controls including 141 subjects from the University of
Kentucky. The controls recruited by NIA-LOAD and NCRAD
did not have a family history of LOAD in a first degree relative,
while those recruited by the University of Kentucky were not
excluded if they had a family history of LOAD. All controls
demonstrated or had a documented history of normal cognitive
function for age, and were evaluated in person or had
neuropathology that did not provide any evidence of LOAD.
Phenotypes. A minimal dataset was available for each person
consisting of demographics, diagnosis, age at onset for cases,
method of diagnosis, Clinical Dementia Rating Scale [51], and the
presence of other relevant health problems. Each recruitment site
used standard research criteria for the diagnosis of LOAD [49].
Participants with advanced disease or those living in a remote
location that could not complete a detailed in-person evaluation
contributed a blood sample, and the site investigator conducted a
detailed review of medical records to document the presence or
absence of LOAD based on the same criteria. The age at onset for
patients with LOAD was the age at which the family first observed
cognitive complaints. For controls, we used their age at the time of
their examination confirming the absence of dementia. For
deceased family members who had undergone a postmortem
brain evaluation, results of neuropathology were used to document
the diagnosis. In general the data from NCRAD was more limited
because families were geographically scattered, requiring medical
record review, telephone cognitive assessment, and neuropathology
data from brain tissue. In total, neuropathological documentation
was available for 306 cases from 199 families, and for 25 controls.
For the purpose of analyses, a clinical case was defined as any
individual meeting NINCDS-ADRDA criteria for probable or
possible AD [49]. We used the NINCDS-ADRDA criteria for
definite AD when clinical and pathological criteria were met or
CERAD pathological criteria [52] for AD when based on
postmortem information alone. Individuals with unspecified
dementia, mild cognitive impairment, or uncorroborated family
reports of dementia were not used in the analyses. Controls were
defined as any individual with no evidence of LOAD, as described
above.
Genotypes. Genome-scan genotyping for all samples was
provided by CIDR (http://www.cidr.jhmi.edu) as a single project
using the Illumina Infinium II assay protocol with hybridization to
Illumina Human610Quadv1_B BeadChips (Illumina, San Diego,
CA, USA). This array contained 592,532 SNPs with a mean
spacing of 5.8 kb, and the minimum genotype completion rate for
any sample released by CIDR was 98.3%. Blind duplicate
reproducibility was 99.99% based on 118 paired samples. We
used only these directly-genotyped data for analysis, without
adding further genotypes via imputation. Genotyping of APOE
polymorphisms (based on SNPs rs7412 and rs429358) for all
samples was performed at PreventionGenetics (http://www.
preventiongenetics.com). Genotyping was carried out in array
tape [53] using allele-specific PCR with universal molecular
beacons [54,55]. DNA sequencing of positive control DNA
samples was completed to assure correct assignment of alleles.
Data Analysis
Overarching approach. Our initial aim was to carry out a
GWAS in the complete European-American (EA) component of
the sample, with and without adjustment for APOE genotype,
while accommodating the presence of related subjects in the
sample. To this end, we had three goals: (1) to try to confirm
recent reports of associated SNPs in the complete EA component
of the sample [42–44]; (2) to determine if reports of residual
association with SNPs near APOE that implicated other genes in
that region [56–58] were robust to full adjustment for APOE
genotype; and (3) to identify new associations in the genome scan,
either in the presence or absence of APOE adjustment. Towards
these goals, we carried out two primary genome scans, based on
absence or presence of adjustment for APOE genotype, with this
adjustment taking into account the full APOE genotype, and not
just presence or absence of the e4 allele, as is commonly done. The
main analysis was based on a comparison of allele frequencies
between cases and controls with adjustment for the effects of
related individuals.
As a consequence of evaluation of the diagnostic indicators of
the validity of assumptions associated with the statistical analyses,
we also investigated possible sources and effects of confounding.
The observations that lead to these additional analyses included
deviation from the expected genome-wide null distribution of the
test statistics, absence of overlap in SNPs identified with evidence
of association across APOE-genotype strata, identification of ethnic
subgroups within the larger EA sample, and recognition that the
APOE allele frequencies differed among these subgroups. We note
that deviation from the expected genome-wide null distribution
was less extreme than has been reported in some other recent
investigations [42,43], but was still sufficiently large to warrant
investigation. Identification of the sources of confounding involved
a number of additional genome scan analyses of the full sample.
No correction for additional testing was imposed on these analyses,
since their primary purpose was investigation of possible
confounding effects, and not of identification of associated SNPs.
Finally, it is important to note that there were complications
introduced by use of a sample containing related individuals,
coupled with need to make comparisons with results from only the
unrelated individuals as part of our broader investigations into
confounding and covariate adjustment. The major advantage of
the full sample is increased power: with the methods used and
assuming a type-I error of 10
27, an allele frequency difference with
,80% power of detection in the complete family-based sample
had a power of only ,20% in the smaller sample of unrelated
subjects. However, use of the complete sample in some analyses as
well as the unrelated subjects in other analyses introduced
constraints, since the identical analysis approaches were either
not always possible or were statistically inappropriate. To the
extent possible, when analyses were carried out on different
datasets or components of a dataset, the analytical methods chosen
were selected to be as comparable as possible. The goal was to be
able address the same question, even if the details behind the
method of analysis differed.
Quality assessment of data and samples. Family structure
both within and across pedigrees was checked and confirmed using
Genome-Wide Association of Alzheimer’s Disease
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relative and Prest ver. 3.0.2 [60] (http://fisher.utstat.toronto.
edu/sun/Software/Prest). A genotyping error rate of 0.03 was
used, with a likelihood ratio .1000 used to flag and review pairs
with potential discrepancies from their stated relationships. For the
analyses presented here, family structure was subsequently used
only to identify a sample of unrelated individuals for use in a series
of sub-analyses.
After stringent filtering on marker quality control indicators and
eliminating monomorphic markers, 565,336 polymorphic autoso-
mal markers from the Illumina panel were used for analysis.
Incomplete genotyping (.2%) lead to elimination of 1.12% of
markers. Additional metrics such as deviation from compatibility
with Hardy Weinberg equilibrium (HWE) in unrelated individuals
(0.2% of SNPs) were only used to further evaluate SNPs with
evidence for association (p,0.00001), because presence of such
disequilibrium is expected in regions with true association and can
be informative in the search for gene-disease associations [61–63].
Of course such disequilibrium can also identify problem SNPs, but
in the absence of evidence for association, such SNPs have little
effect on the overall conclusions. No markers of greatest interest
were eliminated because of such deviation from HWE, although a
small number of such SNPs were eliminated from the tabulation of
those SNPs yielding p,5610
24.
Population structure. Two data sets of unrelated individuals
were constructed, based on self-reported ethnic information
combined with principal component analysis, described below.
The first was drawn from the complete sample, and was of mixed
origin, with all unrelated individuals used together. The sample
was selected by choosing a random genotyped individual from
each family. The second consisted of a sub-sample of individuals
defined as ‘‘European-American-clustering’’, based on the first
analysis (henceforth referred to as European-Americans). From the
latter sample of European-Americans, a dataset containing only
unrelated cases and controls (CCun) was generated such that a
single case was selected from each family. For this purpose,
clinically defined cases were prioritized based on how AD was
defined. Definite AD as defined by NINCDS-ADRDA [49] or
CERAD [52] was selected over probable or possible AD. In
instances where more than one individual met the most stringent
criteria, the case with the lower age of onset was selected.
The complete sample of unrelated individuals was used for
initial investigation of population structure in the sample using
genotypes from the Illumina panel and smartpca from the
Eigensoft package [64]. Initial cluster analysis was based on a
principal component analysis (PCA) of the complete unrelated
sample, with ethnic-specific clusters delineated based on self-
declared ethnicity. This initial analysis was used to refine the
cluster location of the European-American sample within the
larger sample, and to classify subjects with undeclared ethnicity to
define the final sample used for further analysis. For evaluation of
cluster-membership of all subjects, the SNP weights for each
eigenvector were then applied to all remaining family members.
Self-described non-Hispanic European-Americans that clustered
as part of the main European-American cluster were subsequently
flagged and reanalyzed separately, first using unrelated European-
Americans and then applying the SNP weights to all European-
Americans. This separate PCA of the European-American sample
was stimulated by results in the full sample, in which concerns
arose about possible effects of additional stratification. This final
PCA lead us to identify and further investigate and delineate three
subgroups within the European-American sample.
We hypothesized that these subgroups might represent
individuals of northwestern European, southeastern European,
and Ashkenazi Jewish ancestry, based on other studies [65]
coupled with the population makeup near the collection sites. We
used 88 of 159 European-specific ancestry informative markers
(AIMs) tailored to NW European (NW), SE European (SE), and
Ashkenazi Jewish (AJ) ancestry [65] (http://genepath.med.harvard.
edu/,reich/) that were available in our marker panel for eva-
luating this hypothesis, restricting analysis to the markers for which
the minor allele frequency (MAF) was ,0.4 in all three sub-
populations. These were the markers that provided unambiguous
matching of our alleles with those reported previously [65], and
avoided potential allele mismatch due to unclear specification of
allele calling procedures. For these markers, we obtained the
population that best explained each subject by maximizing the
likelihood over all markers under the assumption of independence
of the markers and using the published allele frequencies [65]. The
distributions of the difference in reported vs. observed marker allele
frequencies in each cluster vs. known population were also
investigated. Finally, after assigning subjects to their subgroup
defined by their PCA clustering, allele frequencies were computed
genome-wide for pairs of subpopulations, to determine whether
known strong gene-frequency clines that characterize north-south
gradients in Europe were apparent, such as the regions surrounding
lactase and HLA [66,67].
Kinship estimation. Kinship coefficients estimated from the
data were used for several purposes. This included detecting
cryptic relatedness, quantifying and comparing relatedness, and
correcting for relatedness in statistical tests carried out on samples
that included related individuals. We estimated kinship coefficients
for pairs of individuals in the European-American sample with
Kinship ver. 2.0 (http://faculty.washington.edu/wijsman/
software.shtml) based on methods described in detail elsewhere
[68]. In brief, for each pair of individuals, we maximized the
likelihood for each of the nine condensed identity coefficients [69],
and collapsed these into an estimate of the kinship coefficient. Use
of a maximum likelihood estimate (MLE), rather than a moment
estimate, provides the most accurate such kinship estimates [70],
with superior power and control of type I error in hypothesis
testing, although at modest increased computational cost. We
estimated the kinship coefficients for two groups: the entire group
of European-American subjects, including related individuals
(referred to as the CCall sample), as well as for the three
subgroups: the NW, SE and AJ, as determined by the analyses
described above. Each of these four groups included both related
and unrelated cases and controls. The estimates for the individual
subgroups were used only in analyses that incorporated subgroup
information; in all other situations, the estimates from the CCall
sample were used.
For the purpose of estimating kinship coefficients, we used
11,471 SNPs chosen to be maximally informative and relatively-
uniformly spaced on the reference sequence. Use of higher
numbers of markers adds little additional precision, while adding
unnecessary computational burden [68]. The panel of SNPs was
chosen by restricting use to those with .99% data completion and
a MAF.0.05 in the whole data set, with a minimum interval
between markers of 100 KB, and an attempt to maximize the
MAF. Ultimately, 87% of SNPs used for this purpose had
MAF.0.45 and 95% had MAF.0.4.
Case-control analysis, full sample. All tests of allele
frequency differences in the CCall sample were carried out with
the program cor_chi (http://faculty.washington.edu/wijsman/
software.shtml), using procedures that correct for relationships in
the sample [68]. We used pair-wise kinship coefficients estimated
from the marker data to correct the variance in a chi-square test of
association, in a modification to the approach suggested by
Genome-Wide Association of Alzheimer’s Disease
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and controls as all unaffected individuals, as described above
under Phenotyping. This approach allows for variation in the
realized IBD-sharing within families, as well as incorporating the
effects of additional, unspecified relationships. This approach thus
has somewhat better properties in the presence of related subjects
than a test based only on pedigree-based expected kinship
coefficients [68] or other relationship information from the
pedigree structure alone [38]. The correction for kinship was
carried out either under the assumption that the full European-
American sample represents a single population, or under the
assumption that each of three identified sub-populations represents
a separate population.
For our primary genome scans, we carried out an analysis of the
full sample without adjusting for APOE since this is a common
approach [34,42], as well as an analysis that controlled for APOE
genotype effects. The method of analysis that corrected for the
existence of relatives did not permit use of a covariate-adjusted
model, which is the most common approach for controlling for
specific genotype effects. Instead, we carried out a stratified
analysis (e.g., structured association), which is also a well-
established approach [72]. It is less often used than the former
approach because of the need for large sample sizes, but the large
size of the full sample available to us made this possible. The
consequent number of strata that could be used also allowed a
more subtle accommodation for known differences in LOAD risk
among APOE genotypes [73] than simply adjusting for presence or
absence of the e4 allele. Attention to appropriate use of covariates
is more critical for detection of small than large contributions to
risk and to avoid spurious conclusions about association, so that
this fuller adjustment for APOE genotype was expected to provide
the better model in this context. The strata were based on four
APOE genotype groups consisting of e4/e4, e4/e3, e3/e3, and the
combined sample of e3/e2 and e2/e2 (full adjustment). The e3/e2
and e2/e2 genotypes were combined because they are each
relatively infrequent low-risk genotypes for AD [17]. The e4/e2
genotype was omitted because of small sample size in analysis
alone, and because it was unclear how to combine it with other
genotype(s) to compensate for the small sample size. Analyses were
performed within each stratum, with results also combined across
strata in a Cochran-Mantel-Haenszel 1 df test. Results were
combined across strata by weighting allele frequency differences
and their variances proportional to sample sizes, as well as by
assuming equal weights across strata. For APOE stratified analyses,
for which there were relatives in different strata, this did not fully
adjust for the effect of relationships across strata, resulting in
modest genome-wide inflation, l, of the observed test statistic
relative to that expected, as quantified by the observed vs.
expected median [74]. We therefore corrected the cross-strata tests
by dividing by l as a genome control correction factor [74].
Case-control analysis, unrelated sample. The CCun
dataset was also used in the primary analyses to provide a
comparison with the analysis of the full sample including the
pedigree data, including different effects of adjusting for
covariates. Analyses were carried out both without and with
adjustment for APOE genotype. The primary analyses were based
on logistic regression, using case status as the dependent variable
with an additive model for the test SNP (0, 1 or 2 copies of the
minor allele). Logistic regression, as opposed to an allele-based
test, was chosen because it is insensitive to small deviations from
HWE, and can include APOE genotypes as covariates, rather than
requiring a less-ideal stratified analysis. The smaller CCun dataset
was too small to carry out a stratified analysis, since the small
within-stratum analysis made this statistically inappropriate.
Therefore, to parallel the analysis of CCall as closely as possible
given the different data structure, we included the number of
APOE e4 and e2 alleles as covariates in an additive model (full-
adjustment). This approach efficiently captures most available
haplotype information with the cost of only two degrees of
freedom [75,76], and sufficiently captured the effects of APOE,a s
measured by residual association in the APOE region. For a small
number of diagnostic comparisons of the tests used, we also carried
out analyses with an allele-based test analogous to that used for
analysis of CCall, but without the kinship correction, since there
was little evidence of cryptic relatedness. Finally, further analyses
were undertaken to probe interaction of SNP effects within the
APOE e4/e4 genotype, in order to parallel results obtained in the
CCall sample within e4 homozygotes. For these analyses, we
carried out focused analyses of specific SNPs, using logistic
regression with APOE and test SNP main effects plus an
interaction effect, since the analyses based on CCall suggested a
statistical interaction. The main interest in these analyses was in
the coefficient for interaction.
Adequacyandinterpretationofanalysismodels. Adequacy
of case-control tests was evaluated by computing l [74], and by
verifying the entire distribution of resulting p-values against expected
quantiles. We used quantile difference plots, which better facilitate
visual evaluation of the adequacy of the fulldistribution of results than
do standard QQ plots, by plotting the difference in the negative
logarithm of the observed and expected p-values against the negative
logarithm of the expected p-values. Deviation from the null
distribution over any part of the distribution is an indicator of
possible violation of assumptions behind the test, and therefore
interpretation of the results. A conservative Bonferroni correction was
used initially to adjust for multiple testing, resulting in a threshold of
p=8.8 610
28 (2log(p)=7.05) as a significance threshold that retains
a genome-side significance level of 0.05, given the number of markers
used for analysis. Plotting and evaluation of analysis results was
carried out with R (http://www.r-project.org) and GnuPlot (http://
www.gnuplot.info). In addition, for the analyses based on the CCun
sample, we carried out permutation tests to define empirical
confidence bounds under the null distribution. For these analyses
we permuted the disease status, but kept the genome scan genotyping
intact in order to maintain the LD structure in the genotype data. An
equivalent estimate of the confidence bounds of the test results could
not be obtained for the CCall sample because of the difficulty of
carryingoutthepermutations under the constraints of relationships in
the sample. However, since the CCall sample is larger than the CCun
sample, with greater power, the confidence bounds for the CCun
sample can be taken as a conservative estimate for the CCall sample.
Analysis of confounding in the NIA-LOAD/NCRAD
sample. To evaluate possible sources and effects of
confounding and different approaches to correcting for
confounding, we carried out additional analyses in both the
CCall and CCun samples. Evaluation of the efficacy of each
approach to correcting for confounding was based on examination
of the genome-wide p-value distribution, as a metric of adequacy
of the correction. For comparison to the full-adjustment for APOE,
we carried out a stratified analysis (CCall) and a covariate analysis
(CCun) based only on presence/absence of APOE e4 (e4-
adjustment), since this is a common approach for APOE
adjustment [42,43,57]. Results were combined across strata as
described above. In addition to genome-wide distributions of p-
values, particular attention was paid to the effects of this
intermediate adjustment on evidence for association with SNPs
in the APOE region because of interest in additional potential risk
loci in this region [56–58]. In one set of analyses of CCall,w e
carried out a stratified analysis based on the three identified
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estimated separately within each group. In one analysis of CCun
we included covariate adjustment for the loadings on the first four
European-American-specific principal components [64] as an
evaluation of correction for stratification in the sample.
Direct evaluation of the APOE e4 allele as a source of
confounding was obtained through two analyses, after eliminating
from the analysis all SNPs within 300 KB of APOE. We examined
e4 allele frequency as a function of PCA loading. We also carried
out a genome-wide case-only analysis to compare SNP allele
frequencies in e4 carriers vs. non-carriers among cases from the
CCall sample. This eliminated association attributable to case
status so that residual association, manifested as either genome-
wide deviation of the test results from that expected under the null
distribution or for specific SNPs of interest, could therefore be
attributed to APOE-associated confounding or similar sources of
population structure.
Bioinformatics Analysis
We performed bioinformatics analysis to identify genes that are
locatednear the topSNP signalsfromourown GWAS,orgenes that
are biologically related to the genes at the SNP locations. For this
purpose, we used SNAP and GRAIL (http://www.broadinstitute.
org/mpg/grail/grail.php) to identify candidate genes. SNAP (http://
www.broadinstitute.org/mpg/snap/ldsearch.php) identifies genes,
extendinginbothdirectionsuntilr
2,0.5,whileGRAILsearchesfor
genes that are in the SNP region and that are biologically related to
each other based on the published literature.
Replication Sample and Analysis
As an independent replication of the CUGBP2 association
identified in the main analysis in the presence of APOE e4
homozygotes, we examined a combined sample consisting of a
Caribbean Hispanic cohort, and subjects from the combined
Washington University case-control dataset and the Alzheimer’s
Disease Neuroimaging Initiative (WU-ADNI) [77]. These datasets
were chosen because all had been genotyped on one of the
Illumina platforms and shared multiple SNPs. The Caribbean
Hispanic sample comprised 549 cases and 544 controls from two
studies, including the Washington Heights-Inwood Columbia
Aging Project (WHICAP) study [78] and the Caribbean Hispanic
family study of familial AD [79]. The WU-ADNI data set
comprised 788 EA cases and 643 EA controls. For the replication
analysis, we used a conservative sample of 231 cases and 187
controls from the Caribbean Hispanic sample and 386 cases and
386 controls from the WU-ADNI sample, restricting subjects to
homozygotes for each of the APOE e4 and e3 alleles, respectively,
to avoid the heterogeneity caused by pooling different APOE
genotypes that was identified in our primary analysis. While the
Caribbean Hispanic sample is ethnically different that the
European-American NIA-LOAD sample, this is advantageous
since it reduces the probability of inflated evidence for association
due simply to the shared ancestry of repeated samples from the
same population [80]. SNP genotypes were from the Illumina
HumanHap 650Y panel (Caribbean Hispanics) and several
different Illumina platforms (WU-ADNI). We evaluated a total
of all 24 SNPs in CUGBP2 that were genotyped in all of these
samples as well as in the NIA LOAD sample. APOE genotyping
was based on the same method as that for the NIA-LOAD cohort,
or as described elsewhere [57].
We tested possible association of SNPs in CUGBP2 on LOAD
risk in joint analyses across cohorts. For our primary analysis, we
analyzed only rs201119 in the independent replication cohorts
because this SNP gave the strongest genome-wide-significant
evidence for association in the NIA-LOAD/NCRAD sample in
the APOE e4/e4 stratum. For this analysis we did not apply a
multiple testing correction because it was the single primary SNP
tested for replication. In a second analysis we carried out analysis
of all 24 SNPs that were available in both the replication and
original cohorts, using a Bonferroni correction for multiple testing.
In a final analysis, we combined the CCun component of the
original NIA LOAD/NCRAD cohort with the replication sample,
and carried out the same joint analysis using all of the cohorts. The
analysis model used was stimulated by the APOE genotype-specific
association identified in the main sample, which suggested an
interaction between APOE e4/e4 and rs201119: we used logistic
regression with an additive model for cohort, number of SNP
alleles, APOE genotype (e3/e3 vs. e4/e4), and an interaction
between the SNP and APOE, testing for both a SNP main effect
and an interaction with APOE genotype. The component of the
analysis of interest here was the interaction coefficient, given the
original results that suggested such an interaction.
Results
Sample Used for Analysis
The final genotyped NIA-LOAD/NCRAD cohort consisted of
5,220 subjects. The complete sample was ethnically diverse, with
4,232 who were self-declared European-Americans, and the
remainder180self-declared AfricanAmericansubjects,309Hispanic
subjects, 300 subjects with other backgrounds, and 199 subjects with
no self-reported race and ethnic information. Some individuals
clustered with a group other than their self-reported group, leaving
3839 individuals (Table 1) that clustered as European-Americans
based on a principal components analysis of all unrelated subjects
(Figure1)and wereused inthe CCall sample. Of the 3,839 European-
American subjects, 993 cases and 884 controls were used in the CCun
sample. As expected in a geographically distributed sample from
North America, the fraction of subjects from any one self-reported
ethnic group varied across collection site.
Population Structure
The European-American-specific principal components (PCs)
revealed substructure within the sample. Although apparent with
the first two principal components (PC1 and PC2), three subgroups
were most clearly defined by the first and fourth principal
components (Figure 2). Estimated fractions of each subpopulation
varied across sites (Table 2), with the NW group the largest (90.2%)
sample (Table 2). A few subjects fell between the main clusters, and
were excluded in subsequent subgroup analyses (Figure 2).
Subgroup assignments were strongly supported by likelihood
computations based on European subgroup-specific AIMs, and by
comparisonofallelefrequenciesinthethreegroupswiththoseofthe
AIMs. Large between-group allele frequency differences between
the NW and other groups near lactase on chromosome 2 and HLA
on chromosome 6 [81] further supported these subgroup assign-
ments: e.g., allele frequency differences .0.55 for SNPs near
lactase, as do overall comparison of allele frequency differences
between pairs of populations. Although the median allele frequency
difference was relatively low (,0.04) for all three pairs of
populations (Figure 3A), 7%, 9% and 12% of the markers had a
substantial allele frequency difference of .0.1 in the NW-SE, AJ-
SE, and NW-AJ comparison, respectively. These larger allele
frequency differences coupled with varying fractions of cases from
the different contributing sites (Table 2) predispose to confounding.
APOE allele frequencies also differed among the three sub-
groups, along with a higher fraction of cases relative to the
subgroup sample size drawn from the AJ and SE sub-groups than
Genome-Wide Association of Alzheimer’s Disease
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unrelated controls varied in a manner that is consistent with a
known north-south e4 allele frequency gradient, with higher e4
allele frequencies in northern than southern European populations
[82–84], and with lower e4 frequencies reported in Jewish
populations [85,86]. In these unrelated controls, the e4 allele
frequency was higher in subjects of NW ancestry (0.139) than in
subjects of SW (0.109) or AJ (0.092) ancestry, with the same allele
frequency patterns also apparent in the unrelated (control) family
members, and in the affected individuals (cases). The cumulative
distribution of European-American PC4 values in the whole
European-American sample differed among APOE genotypes in a
manner that was also consistent with existence of sub-structure
(Figure 3B), with similar results observed in the NW group alone
(not shown).
Case-Control Analyses
Genome scans, no APOE adjustment. As expected, SNPs
near APOE provided the strongest genome-wide evidence for
association in the unadjusted analyses (Figure 4A, Table 4). In the
primary analyses, SNP rs2075650 in TOMM40, which is in strong
linkage disequilibrium with rs429358 in our sample (D9=0.70;
r
2=0.45; using the 884 unrelated controls), and which tags the
APOE e4 allele, gave highly significant results in analysis of both
the CCall and CCun sample (p=3.2610
281 and p=6.3610
277,
respectively). The secondary analyses gave similar results with
rs2075650 in the analysis of the ethnic-stratified analysis for the
unweighted combined results, the NW sample, and the AJ sample
(p=1.2610
215, p=3.2610
273, and p=3.7610
28, respectively).
In each of these analyses, six additional SNPs near APOE also
provided very strong support for this association (e.g., in the CCall
sample, p-values ranged from p=4.9610
210 to p=2.9610
224).
Only in the small SE sample was the evidence for association with
rs2075650 merely suggestive (p=0.03), consistent with the
reduced inflation, in this sample, of the e4 frequency in cases
relative to that observed in the other subgroups (Table 3). For this
SE sample, rs7007878 on chromosome 8 at ,29 MB provided the
strongest evidence of association (p=6.5610
26).
Other than SNPs in the APOE region, the region with the
strongest evidence for association in the primary analysis spanned
109.2–109.8 MB on chromosome 8, in which several SNPs (e.g.,
rs1975804,rs1679666,rs1789964)cameclosetoachievinggenome-
widesignificance ineithertheCCunorCCallsample(TablesS1,S2).
Both samples gave similar results: p-values 1.6610
26 to 3.3610
27
in the CCall sample, and 9610
26 to 5.7610
27 in the CCun sample.
A few regions of the genome yielded marginally stronger evidence
than the unadjusted analysis for association in the analysis that
stratified on ethnic subgroup (Figure 4B), but no regions other than
the APOE region reached genome-wide significance. A portion of
this sample has been used previously to investigate 29 SNPs as part
of focused followup analyses [38,40]. However, only two of these
previously-investigated SNPs overlap with our current study, and
neither of these SNPs gave significant results in either the earlier
[38] or current analyses.
Genome scans, APOE full adjustment. In contrast to
unadjusted analysis, the analyses based on a full-adjustment for
APOE genotype identified no SNPs with genome-wide significance in
either the full CCun or CCall samples (Figure 4C, 4D). Complete
adjustment for APOE genotype accounted for most association in the
APOE region. Evidence for association with rs2075650, which had
the strongest evidence for association in the unadjusted analysis, fell
precipitously after adjustment: only modest evidence for association
remained for the CCun sample (p=6.6610
24,T a b l eS 3 )a n d
evidenceforassociationwaseliminatedintheCCallsample(p=0.15).
Analysis of individual APOE genotype strata led to identification
of one novel region with genome-wide-significant evidence of
Figure 1. Principal components analysis of the complete
sample, based on all ethnicities. Red: European-American subjects.
PC1 and PC2: first and second principal component.
doi:10.1371/journal.pgen.1001308.g001
Table 1. European-American–clustering individuals used for analysis.
Ascertainment Study Affected individuals
a Unaffected individuals Total
Subjects Families Mean age at onset (SD) Subjects Families Mean age at exam (SD)
Multiplex fams LOAD
b 1138 475 73.6 (7.2) 986 216 63.8 (10.8) 2124
NCRAD 325 133 72.4 (6.2) 0 0 325
Unrelated LOAD
b 184 184 73.6 (7.7) 1002 1002 75.6 (8.6) 1186
NCRAD 201 201 72.4 (6.1) 3 3 75.7 (2.5) 204
Totals 1848 993 1991 1221 3839
aDefinite, probable, and possible AD diagnoses were 28%, 64%, and 8% of the total sample, respectively, and 34.6%, 63.9%, and 1.5% among affected individuals used
in the CCun sample.
bIncludes 135 control subjects and 6 cases from University of Kentucky.
doi:10.1371/journal.pgen.1001308.t001
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rs201119 provided strong genome-wide-significant evidence of
association within the APOE e4/e4 stratum (p=1.5610
28).
Surrounding SNPs also gave strong results within this stratum
(Figure 5A, Table S4), including rs201099, which also reached
genome-wide significance (p=8.3610
28). Even stronger genome-
wide-significant results wereobtained when analysis was confined to
theAPOE e4/e4 individualsintheNWsubgroup(p=6.6610
29 and
2.2610
28 for rs201119 and rs201099, respectively), eliminating the
possibility that this association was explained by the existence of the
AJ and SE subjects in the sample. SNPs on chromosomes 8 and 6
gave suggestive evidence for association in the APOE e3/e4
(Figure 5B, p=1.0610
26, Table S5) and APOE e3/e3 (Figure 5C,
p=1.2610
26, Table S6) strata. Finally, a region on chromosome 1
was identified with strong evidence for association in the APOE e3/
e2+e2/e2 stratum (Figure 5D, p=8.4610
27).
Bioinformatics results. Table 4 lists genes located on or near
the SNPs with the strongest p-value for each analysis. Several genes
emerged (Table 4), in addition to APOE and related genes (e.g.,
APOC1). The most promising candidate is CUGBP2 (CUG triplet
repeat, RNA binding protein 2; 11,087,265–11,509,495 bp) on
chromosome 10p14, which was associated with the top SNP,
rs201119, identified from the APOE e4/e4 restricted analysis. This
SNP is in the middle of this gene, as is SNP rs201099, also with
genome-wide significant evidence for association.
Replication analysis of CUGBP2. The primary analysis of
CUGBP2 in the replication cohorts supported rs201119 as
associated with LOAD in the presence of APOE e4/e4 (Table 5).
Figure 2. First four principal components (PCs) in the European-American sample alone. Colors represent inferred ancestry. Black:
northwest (NW) Europe; green: southeast (SE) Europe; cyan: Ashkenazi Jewish (AJ); magenta: indeterminate (omitted from subpopulation analyses).
doi:10.1371/journal.pgen.1001308.g002
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(p=0.048, OR=1.43, 95% CI 1.0–2.03 for the same allele as
showed a higher frequency in cases than controls in the CCall e4/
e4 sample). The NIA-LOAD/NCRAD CCun sample similarly
gave significant evidence for an interaction with the same model
(p=0.00016), consistent with the results from the stratified analysis
of the larger CCall sample. Among the 24 SNPs evaluated in the
joint analyses of the replication cohorts, 6 SNPs provided nominal
p-values below 0.05 for interaction with APOE, with p=5.6610
24
for rs62209 (OR=1.75, 95% CI 1.27–2.41), which is significant at
the 1% level after Bonferroni correction. SNP rs201099, which
also provided genome-wide significant evidence for association in
the NIA-LOAD scan, provided nominal evidence of an interaction
in the replication sample (p=9.1610
23). In the joint analysis of
the NIA LOAD/NCRAD, Caribbean Hispanic, Washington
University, and ADNI samples, 12 SNPs were significant for
interaction with APOE at a nominal 5% level, and 6 SNPs
remained significant after Bonferonni correction (p=2.08610
23,
Table 5). The cohorts used for the replication analysis had similar
patterns of linkage disequilibrium between pairs of SNPs in
CUGBP2 (Figure S2), further supporting the evidence for
replication. These results in joint analysis of the replication
samples provide further support for a statistical interaction of
SNPs in CUGBP2 with APOE e4/e4 in conferring AD risk.
Replication of prior GWAS results. SNPs in four genes that
were recently implicated [42–44] each provided initial nominal
evidence of association in our dataset in analysis of the unadjusted
data (Table 6), with the same allele associated with disease risk in
our sample as was previously reported. An additional SNP,
rs597668, near EXOC3L2 [44], was also considered, but because
of its proximity to APOE, was examined in less detail. Two of the
three SNPs highlighted initially with strongest evidence for
association - rs3818361 in CR1 and rs11136000 in CLU - each
reached nominally significant (p,0.05) evidence of association in
the unstratified or unadjusted analyses of the CCun and CCall
samples. SNP rs3851179 in PICALM achieved evidence for
association at this nominal level only in analysis of CCall. The
gene encoding bridging integrator 1 (BIN1) was also noted initially
at a lower threshold of significance [42] with stronger results in a
recent replication analysis [44], and gave nominally significant
results in the unstratified and unadjusted analyses of our sample
for rs7561528 in both CCun and CCall, and for rs744373 in CCun
(Table 6). In addition, five of the six additional SNPs that were in
these four genes in our genotyping panel achieved nominal
significance in the unstratified analysis of the CCall sample, and
two SNPs achieved nominally significant results in unadjusted
analysis of the CCun sample (Table 6).
Figure 3. Cumulative distribution of absolute value of allele frequency differences between subpopulations and APOE genotypes.
Panel A: subjects from NW and SE (dotted line), AJ and SE (dashed line), and NW and AJ (solid line) groups. Panel B: cumulative distribution of
European-American PC4 values as a function of APOE genotype for e4 homozygotes (dotted line), e4 heterozygotes (dashed line); genotypes with no
e4 (solid line). In panel A, the horizontal axis is truncated at 0.25 despite a few rare allele frequency differences that extend to 0.59; in panel B the
vertical axis is only presented for the upper quartile of the distributions, where the curves are differentiated.
doi:10.1371/journal.pgen.1001308.g003
Table 2. Estimated subpopulation membership for the 17
largest individual contributing sites.
Subpopulation %
Site
a N
b NW SE AJ case %
A 662 93.8 0.8 5.4 99.4
B 504 96.8 1.8 1.4 42.3
C 478 96.7 1.7 1.7 10.9
D 410 76.6 2.4 21.0 40.2
E 398 93.2 1.5 5.3 33.8
F 361 97.5 1.1 1.4 38.2
G 351 97.2 1.4 1.4 49.8
H 222 94.6 1.8 3.6 70.0
I 147 98.0 0.7 1.4 35.5
J 144 99.3 0.7 0.0 52.7
K 139 95.0 3.6 1.4 45.1
L 92 64.1 17.4 18.5 32.5
M 87 75.9 12.6 11.5 39.1
N 67 76.1 19.4 4.5 30.8
O 65 89.2 1.5 9.2 62.7
P 65 70.8 9.2 0.0 43.5
Q 65 83.1 16.9 0.0 49.2
aSites that each contributed .50 European-American subjects.
bNumber of subjects.
doi:10.1371/journal.pgen.1001308.t002
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The distribution of p-values obtained from the unadjusted genome
scans deviated from a uniform distribution, suggesting the presence of
uncorrected confounding. This effect was mild near the median test
value (l=0.97forCC un, l=1.02forCC all)b u tm o r ea p p a r e n ti nt h e
tails of the distribution, providing evidence for potential confounding in
analysis of both samples (Figure 6A, 6B; magenta points; Figure S2).
Some of the deviation from the null distribution is likely to be
attributable to the greater sensitivity to HWD for the allele-based tests
than for logistic regression in CCun (Figures S2, S3, CCun results).
However, deviation from the null distribution in the direction of an
increased type I error over the nominal level was especially marked in
the upper 0.1% of the tail of the distribution for the unadjusted analysis
of the CCun sample even under analysis with logistic regression (Figure
S4), and in the upper 1% for the CCall sample (Figure 6A, 6B, magenta
points). The excess fraction of small p-values was not explained by
SNPs in the APOE r e g i o n( F i g u r e6 C ) ,s o m eo fw h i c hh a d ,a se x p e c t e d ,
much more extreme p-values. This deviation from the null distribution
was not explained by inadequate correction for relationships in the
CCall sample since the same excess pattern of extreme p-values
occurred in the analysis of both the CCun and CCall samples, and over
a wider range of p-values when the CCun sample was analyzed with a
chi-square test instead of with logistic regression (Figure S2). Control
for test statistic inflation was also not achieved by incorporation of the
first four principal components as covariates [64] (Figure 6A, grey
points; Figure S3), or by restricting analysis to the more uniform NW
group (Figure 6B, grey points).
Two sources of evidence suggested that an important source of
potential confounding was APOE genotype. The first was the effect
of adjustment for APOE genotype, which had a notable effect on
the distribution of resulting genome-wide p-values. Simple
adjustment of APOE through binary e4-status yielded a distribution
of p-values that was closer to a uniform distribution than was
obtained from unadjusted analysis. However, deviation from the
expected null distribution was still evident (Figure 6A, 6B, cyan
points), and there was still evidence for association with SNP
rs2075650 near APOE (Figure 6C) in both the unrelated and
related samples (p=1.5610
29 for CCun, and p=1.2610
27 for
CCall). The full APOE adjustment achieved the best control of the
null distribution of p-values (Figure 6A, 6B, black points), and
produced close to the expected uniform distribution of p-values
under the null distribution (Figure S3). Addition of the PCs as
covariates alone did not produce the desired distribution of p-
values (Figure S4, Table S7) and in addition to the full APOE
adjustment in the CCun sample did not provide further
improvement to the distribution of p-values over the APOE
adjustment (Table S8 versus Table S3). This analysis also
eliminated all statistically significant association with SNPs in the
APOE region (Figure 6C), and evidence for adequate genomic
control within each APOE stratum was reasonable (l=0.997, 1.02,
1.009, 1.003 for the e4/e4, e4/e3, e3/e3 and e3/e2+e2/e2 strata,
respectively). A second source of evidence for confounding or
population stratification was obtained from the results from the
case-only analysis: the genome-wide distribution of p-values from
the allele frequency comparison in e4 carriers vs. non-carriers in
the case-only sample also showed an overall deviation from the
expected null distribution in the direction of an excess of small p-
values (Figure 7). This indicates that there are many markers that
are correlation with APOE in the highly-ascertained case sample.
Effect of confounding on replication SNPs. Association
between LOAD and a subset of the replication SNPs showed
evidence of APOE-induced confounding. Evidence for association
with SNPs in PICALM was highly sensitive to adjustment for APOE
genotype (Table 6), suggesting the possibility of confounding. Results
from the case-only analysis supported this interpretation: differences
in allele frequencies among cases who were e4 carriers vs. non-
carriers were nominally significant (p,0.05) or close to significant for
all of the four SNPs evaluated in PICALM: p=0.0047, 0.0184,
0.0524, and 0.0222 for rs541458, rs543293, rs7941541, and
rs3851179, respectively. Furthermore, for all four SNPs, the pattern
of allele frequencies in cases and controls, and among the individual
APOE genotypes in the cases, was consistent with such confounding:
the allele that was associated with higher risk of case-status in the
original case-control analysis always had the highest allele frequency
among e4/e4 cases and the lowest allele frequency among e3/e3
cases, with the allele frequency intermediate in the e3/e4 cases. For
example, for rs3851179, the major allele, C, had a frequency of 0.655
in cases and 0.634 in controls, and had allele frequencies of 0.618,
0.665, and 0.67 in e3/e3,e3/e4,a n de4/e4cases,respectively.Similar
results were obtained for rs597668 near EXOC3L2,w i t he v i d e n c ef o r
association in the absence of APOE adjustment (p=0.0007 in CCall)
weakening considerably with full adjustment for APOE (p=0.67), and
with very strong evidence for allele frequency differences between e4
carriers and non-carriers in the case-onlyanalysis(p=6.79610
28).In
contrast, there were no significant allele frequency differences
identified in case-only analyses for the SNPs in Table 6 for CR1,
CLU and BIN1 (p=0.31–0.74).
The evidence for association with SNPs in some of these four genes
was also dependent on ethnic stratification, suggesting a further or
alternative source of confounding. For all tested SNPs in CR1,
evidence for association in the CCall sample, while modest in each
sub-population, was consistent across subpopulations and therefore
strengthened in analysis that stratified on ethnic subgroup (Table 6).
Evidence for association with rs7561528 in BIN1 also remained
Table 3. APOE allele frequencies in European-American subjects.
Unrelated controls Related controls Cases
Subjects Count
a Allele Count Allele Count Allele
Sample N 2N e2 e4 2N e2 e4 2N e2 e4
CCall
b 3839 1402 0.097 0.138 2566 0.054 0.255 3678 0.023 0.465
NW 3446 1244 0.100 0.139 2336 0.054 0.264 3312 0.024 0.472
SE 110 46 0.043 0.109 64 0.047 0.141 110 0.018 0.291
AJ 214 76 0.079 0.092 124 0.048 0.185 228 0.017 0.448
aNumber of alleles.
bA few subjects were missing APOE genotype data.
doi:10.1371/journal.pgen.1001308.t003
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association with CLU and PICALM was only present in the
unstratified analysis of the full sample, and in the NW group, with
no support from the AJ and SE samples or from the ethnically-
stratified analysis. Adjustment for ethnic subgroup did not fully
correct for residual sources of correlation, as judged by the quantile
difference plot for the NW sample (Figure 6B), suggesting that
residual sources of correlation exist, even after correcting for
relationship information. Similarly, evaluation of the quantile
difference plot for the analysis of the CCun sample, using principal
component loadings to correct for possible ethnic variability, also
failed to produce the desired genome-wide quantile difference plot
(Figure 6A).
Discussion
Analysis of the NIA-LOAD/NCRAD sample indicates that
unraveling susceptibility to LOAD is complex even when
individuals from genetically-loaded multiplex families are includ-
ed. As with other studies, support for the association between
Figure 4. Genome scan of European-American subjects. Panel A: CCall sample analyzed as a single population; panel B: stratified analysis of
CCall sample that accounts for three subpopulations (NW, SE, AJ); panel C: stratified analysis of CCall sample across four APOE genotypes; panel D:
CCun sample, with covariate adjustment for the number of e2 and e4 alleles. Plots have been truncated at 2log10p=10 on the vertical axis to more
easily visualize results for most of the genome. Multiple SNPs near APOE on chromosome 19 yielded 2log10p&10 in the analyses that did not control
for APOE (Panels A and B, see text for details), and are represented by a single triangle at the top of each such panel. Horizontal line shows genome-
wide significance level.
doi:10.1371/journal.pgen.1001308.g004
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this association, we were able to identify a potential novel locus,
CUGBP2, on chromosome 10p14 with genome-wide significant
evidence of association within the highest-risk APOE e4/e4
stratum, with replication in an independent sample. We also
found support for association with recently-reported SNPs in CLU
and BIN1, and to a lesser extent with CR1. However, we found
that the strong APOE association also introduced a source of
structure into the sample that had effects that were detectable
through standard evaluation of analysis results. Our results provide
strong evidence that this correlation with APOE explains the
association in this sample with some, but not all, previously-noted
SNPs, including PICALM and the recently-proposed association
near EXOC3L2, both of which have significantly different allele
frequencies in AD cases who are carriers vs. non-carriers of the
APOE e4 allele.
Detection of true risk loci in a GWAS of LOAD requires careful
attention to potential sampling biases [87]. Large samples such as
ours are necessary for detecting modest associations, but such
samples usually involve multiple collection sites, introducing the
potential for confounding or other complications. Consistent with
this, across our participating sites we found variability in the
numbers of cases and controls, the fraction of underlying
identifiable ethnic subgroups, differences among subgroups in
terms of APOE genotype frequencies, and differences in APOE
genotype distributions as a function of an indicator of genetic
differentiation. None of this is surprising, given the history of US
colonization and immigration coupled with differentiation among
European populations [81,88]. Other large samples in Europe and
other locations are likely to have similar issues, as suggested by
genome-wide inflation factors reported by recent studies [42,43]
that were higher than those in our study. Appropriate accommo-
dation for confounding or structure when it is present can provide
both protection against false positive associations, as well as
increased power to detect associations that are confined to a subset
of the sample, as we have demonstrated as part of our
investigations surrounding the influence of APOE on our results.
We also found that common methods failed to provide the
necessary correction for APOE-induced associations, including use
of principal components adjustment [64] and genomic control
[74]. Together these observations have important implications for
interpretation of results from other large combined samples.
Accommodation for APOE genotype was key for obtaining
appropriate genomic control in our sample. Incorporation of
individual APOE genotypes, as opposed to the more typical use of
presence or absence of e4, resulted in the closest approximation to a
uniform distribution of p-values over a wide range of the test results.
This likely resulted in a reduction in false positive association results
since such control must be achieved before accepting evidence of
association. Not only were our genome-wide results impacted by
adjustment for APOE genotypes, but the support for some SNP
associations from previous studies was similarly affected. For the
SNPs that were most sensitive to APOE-adjustment, the allele
frequencies differed among cases as a function of APOE genotype,
suggesting a relatively simple diagnostic for which SNPs require
adjustment for APOE as part of the analysis: for such SNPs, a full
adjustment for APOE genotype may be critical for genomic control
in part because of allele frequency differences among populations
[82,89]. These differences could lead to structure in the ascertained
sample through variability in disease risk or survival in underlying
subpopulations, as seen across the subpopulations identified in this
sample. It thus may represent a corollary to confounding through
ascertainment of cases, possibly related to the effects discussed by
Voight and Pritchard [90]. Alternatively, it may represent statistical
interactionresultingfrompopulationstratification,whichcancreate
mild linkage-disequilibrium between many markers that are on
different chromosomes, with the strongest such LD occurring
between loci with the largest frequency differences across
populations. Such genome-wide effects of population stratification
have recently been demonstrated both in simulated data, and in
breast cancer, where there is association, detectable in cases,
between SNPs in LCT and genome-wide SNPs, with a similar
genomewide shift in the distribution of p-values [91]. Such
adjustments for loci with strong effects may also be important in
other diseases with such strong risk loci.
Stratification on APOE genotype did facilitate the identification
of a novel region with genome-wide significant evidence for
association on chromosome 10p14, which replicated in a second
sample consisting of three additional cohorts. This region was
identified only in the APOE e4/e4 stratum or in a logistic analysis
that contrasted e4 and e3 homozygotes in a model with an
interaction term with APOE. The relative infrequency of e4
homozygotes means that these results will need to be further
investigated in other large data sets to determine its importance.
Table 4. SNPs with strongest evidence for association under each analysis condition.
SNP Group p-value Chr
a Position (bp) Allele
b Freq-control Freq-case OR
c Genes
rs2075650 CCall 2.95610
281 19 50087459 A 0.820 0.615 0.35 APOE, APOC1, APOC4 TOMM40, PVRL2
rs2075650 Ethnic stratified 1.18610
215 19 50087459 A APOE, APOC1, APOC4 TOMM40, PVRL2
rs2075650 AJ 3.74610
28 19 50087459 A 0.875 0.639 0.25 APOE, APOC1, APOC4 TOMM40, PVRL2
rs2075650 NW 3.21610
273 19 50087459 A 0.814 0.608 0.35 APOE, APOC1, APOC4 TOMM40, PVRL2
rs7007878 SE 6.53610
26 8 29098372 A 0.446 0.755 3.83 KIF13B
rs10489216 APOE e3e2+e2e2 8.44610
27 1 166869486 G 0.780 0.5 0.28 DPT, XCL1
rs7814569 APOE e3e3 1.18610
26 8 81252421 A 0.930 0.871 0.51 ZBTB10, TPD52
rs4145454 APOE e4e3 1.03610
26 6 164492026 G 0.706 0.786 1.53
rs201119 APOE e4e4 1.52610
28 10 11089983 A 0.793 0.939 4.02 CUGBP2, PITRM1
rs2673604 APOE stratified 2.60610
26 8 133480789 A KCNQ3
aChromosome.
bAllele depicted is the allele on the Illumina TOP strand.
cOdds ratio with respect to allele noted.
doi:10.1371/journal.pgen.1001308.t004
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the NIMH AD sample [92], may be preferable in such analyses,
since such sample ascertainment may have contributed to the
detection of this locus through the resulting presence of a relatively
high fraction of APOE e4 homozygotes. It is also worth noting that
an earlier linkage analysis of a subset of the families used here,
based on the Illumina 6K mapping panel, obtained lod scores for
rs1537626 of 2.35 in the whole sample and 1.6 in an analysis that
retained only APOE e4-positive cases. This SNP is within 10 cM of
rs201119 [93]. This SNP was not on the marker panel used here,
nor was rs201119 on the earlier 6K marker panel, preventing
further comparison of results. It is also possible that analysis within
the high-risk APOE e4/e4 genotype improved detection of this
region in the current study by increasing the within-genotype
penetrance, possibly by affecting age-at onset. If so, this would be
similar to the strategy of identifying risk- or age-at-onset modifier
loci on a background of a single, early-onset AD mutation [94–
96]. The implicated region on chromosome 10p14 contains the
genes CUGBP2 and PITRM1. CUGBP2 has one isoform that is
expressed predominantly in neurons, with experimental evidence
suggesting involvement in apoptosis in the hippocampus [97], with
both these observations consistent with a role in pathogenesis of
Alzheimer’s disease. PITRM1 can degrade amyloid b4 APP
protein when it is accumulated in mitochondria [98].
Our results both support and refute recently proposed
association with SNPs in several genes [42–44]. Evidence for
Figure 5. Stratified analysis of APOE-defined subgroups of all European-American subjects. Panels A: e4/e4 genotype, B: e3/e4 genotype;
C: e3/e3 genotype; and D: e2/e2+e2/e3 combined genotype. Horizontal line shows genome-wide significance level.
doi:10.1371/journal.pgen.1001308.g005
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and CR1 was relatively robust to APOE adjustment within this
European-American sample, with evidence for BIN1 and CR1 also
obtained across an analysis that conditioned on ethnic back-
ground. Recent reports by others that include portions of the
sample we used here also report evidence for association with
PICALM [99,100], but did not report the results of quality control
analyses that allow evaluation of adequacy of correction for
confounding. In our analyses, with correction for sources of
confounding, evidence for association with SNPs in PICALM and
EXOC3L2 was much less convincing than for these other three loci
because of the exquisite sensitivity to APOE adjustment. One
interpretation of sensitivity of these associations to APOE
adjustment is that this statistical interaction is indicative of
biological interaction in an analysis that includes a subset of the
current sample [99]. However, the differences in SNP allele
frequencies across APOE strata within cases that we showed here
coupled with information demonstrating the existence of popula-
tion stratification raise concerns that the original associations for
these latter SNPs may represent confounding or other aspects of
sample or population structure. This could include linkage
disequilibrium with APOE, even for unlinked markers. Further
investigation in genetically more diverse populations will still be
necessary to clarify even the role of SNPs with positive evidence
for association, because shared history can lead to spurious
replication in samples drawn from the same population [80].
The results presented here and in other GWAS reports of LOAD
underscore the view that such studies do not necessarily identify the
specific genetic alterations contributing to disease risk. Rather, they
are useful in identifying genes or gene pathways involved in disease
pathogenesis or risk. In that sense, GWAS represents a method of
screening the genome for genes that may also contain rare variants.
While the large number of subjects in current GWAS provides a
benefit in terms of perceived statistical power, it comes at a price.
For example, despite the very low p-values representing genome-
wide statistical significance, the effect sizes in most recent GWAS
involving LOAD are small. It has also been suggested that different
significance thresholds as a function of sample size are needed in
order to balance power against the false-discovery rate [101], with
very large studies requiring more stringent thresholds. This means
that subtle differences in the genetic architecture of either the cases
or the controls become more important with increasing sample
sizes. In this situation some of the ‘‘significant’’ differences in allele
frequency may also represents differences in ancestral origins rather
Table 5. Significance of SNPs in CUGBP2 in prediction of disease risk.
CCall APOE e4/e4
stratum Caribbean Hispanic+WU+ADNI CCun+Hispanic+WU+ADNI
SNP Allele
a N
b P
c N
b OR
d 95% CI P
e N
b OR
d 95% CI P
e
rs11256915 A 408 0.286 1435 1.25 0.95–1.68 0.125 2382 1.43 1.13–1.83 3.3610
23
rs2146551 A 407 0.055 1447 1.16 0.86–1.56 0.331 2393 1.35 1.05–1.73 0.018
rs731229 G 408 0.140 1444 1.16 0.83–1.62 0.378 2390 1.22 0.93–1.60 0.142
rs992193 A 408 0.313 1446 1.12 0.84–1.52 0.439 2391 1.20 0.95–1.53 0.118
rs2146553 G 408 0.033 1445 0.83 0.60–1.15 0.259 2392 0.81 0.63–1.05 0.106
rs10795839 G 408 0.488 1435 0.86 0.3–1.18 0.361 2382 0.86 0.66–1.14 0.305
rs1928724 A 407 0.698 1447 0.93 0.69–1.26 0.646 2394 0.94 0.72–1.23 0.655
rs1928722 A 408 0.789 1434 0.89 0.65–1.23 0.493 2381 0.88 0.66–1.16 0.371
rs201070 A 408 0.201 1446 0.96 0.71–1.29 0.793 2392 1.11 0.87–1.41 0.406
rs201071 A 407 0.018 1447 1.19 0.79–1.81 0.403 2394 1.49 1.06–2.11 0.022
rs201074 A 408 4.5610
23 1433 0.69 0.48–1.00 0.052 2380 0.68 0.52–0.91 7.9610
23
rs62209 C 402 3.8610
23 1439 1.75 1.27–2.41 5.6610
24 2371 2.04 1.56–2.67 1.6610
27
rs201082 G 408 0.096 1435 1.61 1.14–2.29 7.5610
23 2382 1.79 1.35–2.38 5.1610
25
rs201097 A 408 0.509 1447 0.83 0.43–1.58 0.561 2394 0.75 0.46–1.22 0.248
rs201099 A4 0 8 8.3610
28 1447 1.56 1.12–2.18 9.1610
23 2393 1.92 1.47–2.56 3.4610
26
rs201100 G 408 0.019 1433 0.65 0.45–0.95 0.024 2380 0.68 0.52–0.89 4.9610
23
rs201119 A4 0 8 1.5610
28 1447 1.43 1.00–2.03 0.048 2394 2.08 1.53–2.79 2.1610
26
rs201124 A 408 1.3610
26 1423 1.43 1.00–2.06 0.048 2370 1.82 1.34–2.46 1.2610
24
rs7099713 A 408 2.3610
24 1435 1.16 0.65–2.06 0.618 2381 1.45 0.94–2.22 0.096
rs1547221 G 408 4.4610
25 1447 1.43 0.88–2.31 0.153 2394 1.82 1.24–2.64 1.9610
23
rs913918 A 408 0.565 1434 1.47 1.04–2.09 0.029 2380 1.47 1.11–1.98 7.8610
23
rs11256951 G 408 0.154 1435 0.95 0.70–1.28 0.740 2382 1.06 0.84–1.36 0.604
rs1999207 A 408 0.914 1447 0.92 0.67–1.24 0.568 2394 0.88 0.69–1.15 0.361
rs932918 A 407 0.908 1447 1.22 0.85–1.74 0.279 2392 1.12 0.84–1.50 0.420
aAllele depicted is the allele with higher frequency in the APOE e4/e4 cases than e4/e4 controls, as denoted on the Illumina TOP strand.
bSample size.
cP-value for relationship-corrected chi-square test of allele frequency differences.
dInteraction odds ratio with respect to allele noted based on logistic regression model.
eP-value for interaction coefficient of logistic model.
doi:10.1371/journal.pgen.1001308.t005
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lead to further biological insights. As we have shown here, genetic
variability within European-American groups exists and can affect
analyses of association. Moving forward, GWAS in LOAD should
consider more detailed care to control for population stratification
or APOE genotypes prior to drawing firm conclusions about
associations. In this sense bigger studies of LOAD or of other
diseases with similar influential risk loci may not always be better, if
the increases in sample size result in added data structure or
confounding.
Supporting Information
Figure S1 Flow chart of source and number of subjects used to
generate the NIA-LOAD/NCRAD resource sample.
Found at: doi:10.1371/journal.pgen.1001308.s001 (0.09 MB PDF)
Figure S2 Linkage disequilibrium among all pairs of 24 SNPs in
CUGBP2 on chromosome 10 in the NIA LOAD/NCRAD
sample, the Caribbean Hispanic sample, and the Washington
University/ADNI sample. For SNP pairs with a log10(Lr).2
supporting D9.0, where Lr is the likelihood ratio under the
estimated D9 versus absence of disequilibrium, bright red indicates
D9=1, while shades of red/pink indicate D9,1, with the value as
indicated. For SNP pairs with a log10(Lr),2 supporting D9.0,
blue represents D9=1, and white represents other values of D9.
Found at: doi:10.1371/journal.pgen.1001308.s002 (0.24 MB
PDF)
Figure S3 QQ (top) and quantile difference (bottom) plots for
analysis of unadjusted European-American samples for all but 95
SNPs near APOE. For quantile difference, vertical axis is the
negative logarithm of the difference in the observed and expected
p-values. CCall: grey diamonds and cyan squares, showing results
without and with adjustment for relationships, respectively,
illustrating the large deviation of the p-value distribution that
occurs in the absence of adjustment for relationships. CCun: black
diamonds and magenta circles, representing chi-square tests of
allele frequency differences and logistic regression, respectively,
illustrating deviation from the null distribution in the chi-square
analysis compared to the trend test from logistic regression. Green
line: expectation under the null distribution.
Found at: doi:10.1371/journal.pgen.1001308.s003 (1.22 MB
PDF)
Figure S4 Quantile difference plot of analysis model results of the
CCun sample. Points represent the negative logarithm of the
difference between observed and expected p-values, and lines
represent the upper 95% confidence bounds. Analyses are
represented by black triangles and dashed line: test of allele
frequency difference; magenta circles and line: logistic regression
with no adjustment for covariates; grey diamonds: logistic regression
with adjustment for the first four principal components; cyan
squares: logistic regression with adjustment for the number of APOE
e2a n de4 alleles; and the blue line: confidence bound for logistic
Figure 6. Quality control evaluation of association tests in the CCun and CCall samples. Panels A, B: Quantile difference plots for
association tests excluding SNPs in the APOE region; and panel C: 2log10(p) for the same analyses for the 95 SNPs in the APOE region. For panels A
and B, results are shown, for N tests, as the difference of the i
th of N ordered observed (2log10(pi)) and expected (2log10(i/N)) quantiles plotted
against the expected quantiles. A: results for the CCun sample, with grey: PCA adjusted; magenta: unadjusted analysis; cyan: e4 adjustment; black: full
adjustment. B: results for the sample containing related individuals; grey: unadjusted analysis of NW subgroup; magenta: unadjusted analysis of CCall;
cyan: e4-stratified analysis of CCall; black: full adjustment. C: UN depicts results for analysis of CCun; REL depicts results for analysis of the larger sample,
in both cases for the same four conditions and colors as in panels A and B.
doi:10.1371/journal.pgen.1001308.g006
Figure 7. Quantile difference plot of tests of allele frequency
differences in APOE e4-carrier versus non-carrier cases. SNPs in
the APOE region are not included.
doi:10.1371/journal.pgen.1001308.g007
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logistic regression conditions were essentially identical).
Found at: doi:10.1371/journal.pgen.1001308.s004 (0.25 MB
PDF)
Table S1 SNPs with p,5610
24 for allele frequency comparisons
in cases versus controls from the full European-American sample
(CCall), after eliminating SNPs with low genotype completion rates
or that failed the test for Hardy-Weinberg equilibrium (7 SNPs) as
described in the quality control analyses under Methods. Results
were further restricted to SNPs with a total count of the minor allele
across both cases and controls that exceeds 20, since caution in the
interpretation of results is required in any case where the total
number of minor alleles is small. The Odds Ratio (OR) shown is the
allele-based OR for the allele shown (the Illumina TOP strand
allele), and the pair of allele counts for each diagnostic class of
individuals gives the count for the allele on the TOP strand first.
Found at: doi:10.1371/journal.pgen.1001308.s005 (0.03 MB
TXT)
Table S2 SNPs with p,5610
24 for allele frequency compar-
isons in cases versus controls from the unrelated European-
American sample, CCun, for analysis based on logistic regression
without additional covariates. Results were further restricted to
SNPs with a total count of the minor allele across both cases and
controls that exceeds 20, as in Table S1. The Odds Ratio (OR)
shown is the OR attributable to 1 copy of the A1 allele. The two
possible alleles (A1 and A2) are shown with both the forward
strand and Illumina TOP strand coding. Genotypes for the three
numbers for each of the cases and controls are the number of such
individuals who are homozygous for the A1 allele, heterozygous,
and homozygous for the A2 allele, respectively. P-values for tests
for deviation for HWE in controls are also shown.
Found at: doi:10.1371/journal.pgen.1001308.s006 (0.04 MB
TXT)
Table S3 SNPs with p,5610
24 for allele frequency compar-
isons in cases versus controls from the unrelated European-
American sample, CCun, for analysis based on logistic regression
with adjustment for the number of APOE e2 and e4 alleles. See
legend to Table S2 for further explanation of columns.
Found at: doi:10.1371/journal.pgen.1001308.s007 (0.04 MB
TXT)
Table S4 SNPs with p,5610
24 for allele frequency compar-
isons in cases versus controls from the APOE e4/e4 homozygotes
in the European-American sample, CCall. No SNPs were removed
because of deviation from HWE. Conditions for presentation of
SNPs are described in legend to Table S1.
Found at: doi:10.1371/journal.pgen.1001308.s008 (0.03 MB
TXT)
Table S5 SNPs with p,5610
24 for allele frequency compar-
isons in cases versus controls from the APOE e4/e3 heterozygotes
in the European-American sample, CCall. 5 SNPs were removed
because of deviation from HWE. Conditions for presentation of
SNPs are described in legend to Table S1.
Found at: doi:10.1371/journal.pgen.1001308.s009 (0.02 MB
TXT)
Table S6 SNPs with p,5610
24 for allele frequency compar-
isons in cases versus controls from the APOE e3/e3 homozygotes
in the European-American sample, CCall. 5 SNPs were removed
because of deviation from HWE. Conditions for presentation of
SNPs are described in legend to Table S1.
Found at: doi:10.1371/journal.pgen.1001308.s010 (0.02 MB
TXT)
Table S7 SNPs with p,5610
24 for allele frequency compar-
isons in cases versus controls from the the unrelated European-
American sample, CCun, for analysis based on logistic regression
with adjustment for the first four principal components. Additional
conditions are as described in Table S2.
Found at: doi:10.1371/journal.pgen.1001308.s011 (0.05 MB
TXT)
Table S8 SNPs with p,5610
24 for allele frequency compar-
isons in cases versus controls from the the unrelated European-
American sample, CCun, for analysis based on logistic regression
with adjustment for the first four principal components and for the
number of APOE e4 and e2 alleles. Additional conditions are as
described in Table S2.
Found at: doi:10.1371/journal.pgen.1001308.s012 (0.04 MB
TXT)
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